| Literature DB >> 27088717 |
Emilia Grecka1,2, Malgorzata Statkiewicz3, Agnieszka Gorska4, Marzena Biernacka5, Monika Anna Grygorowicz5, Marek Masnyk6, Marek Chmielewski6, Katarzyna Gawarecka7, Tadeusz Chojnacki7, Ewa Swiezewska7, Maciej Malecki4.
Abstract
Entities:
Mesh:
Substances:
Year: 2016 PMID: 27088717 PMCID: PMC4835110 DOI: 10.1371/journal.pone.0153633
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Structure of Amino-Prenols, the AP molecule contains an polyisoprenoid chain composed of n isoprene residues.
Fig 2Gel retardation analysis with different carrier:pDNA complexes at various N/P ratios (of amino-group of the carriers to the phosphate group of the nucleic acid).
(a) AP-11:pDNA, (b) AP-15:pDNA, (c) AP-7:pDNA, (d) AP-8:pDNA, (e) PEI:pDNA. M- molecular weight size marker 1kb+.
Fig 3Evaluation of transfection efficiency of B16-F10 cells transfected with use of carrier:pDNA complexes.
(a) Percentage of GFP-positive cells transfected with complexes: AP:pGFP at different N/P ratios (r = 1.7 for AP-7, AP-8, AP-11, r = 2.0 for AP-15) and AP-15/DOPE:pGFP, AP-15/DOPE/DMEM:pGFP lipoplexes containing 2.5 μg of lipids/μg of pGFP, analysed by FACS; Ap- significant difference from AP-15 treatment, At- significant difference from Attractene treatment, L- significant difference from Lipofectamine treatment, P- significant difference from PEI treatment, (b) Activity of β-galactosidase in cells transfected with complexes: AP-11:pLacZ, AP-15:pLacZ, PEI:pLacZ, at r = 2.0–2.5 N/P ratio, studied by β-Gal test; *P<0.05, **P<0.005. Transfections were performed using 4 μg of respective pDNA.
Fig 4(a) cell viability and (b) total cell number of B16-F10 cells transfected with AP:pGFP complexes at various N/P ratios (r = 1.7 for AP-7, AP-8, AP-11, r = 2.0 for AP-15), or with AP-15/DOPE:pGFP and AP-15/DOPE/DMEM:pGFP lipoplexes at 2.5 μg of lipids/μg of pDNA dose, analysed by FACS.
Transfections were performed with the use of 4 μg of pDNA. *P<0.05, **P<0.001.
Fig 5TIMP2 protein expression in B16-F10 cells assessed by Western blot in.
(a) cell lysates, (b) media from cells. (c) Control Gapdh protein level in cell lysates. Lines: 1- B16-F10 cells, 2- B16-F10 cells transfected with AP-15/DOPE:pGFP, 3- B16-F10 cells transfected with AP-15/DOPE:pTIMP2.
Fig 6Number of viable cells in samples treated with the various APs / AP-based reagents alone (grey bars: AP-7, AP-8, AP-11, AP-15, AP-15/DOPE, AP-15/DOPE/DMEM) and AP:pGFP / AP-15 and DOPE-containing complexes (patterned bars: AP:pGFP: AP-7, AP-8, AP-11 r = 1.7, AP-15 r = 2.0; AP-15/DOPE:pGFP, AP-15/DOPE/DMEM:pGFP 2.5 μg of lipids/μg of pDNA), analysed by FACS.
Transfections were performed with the use of 4 μg of pDNA. *P<0.05.
Effect of transfection of B16-F10 cells with AP-15/DOPE:pDNA complexes on expression of lipid metabolism-related gene.
| Gene | B16-F10 | B16-F10/AP-15/DOPE:pSec(fold change relative to control ± SD) | B16-F10/AP-15/DOPE:pTIMP2(fold change relative to control ± SD) | Involvement in cellular process |
|---|---|---|---|---|
| 1 (0.56–1.8) | Reduction of cellular level of cholesterol | |||
| 1 (0.56–1.8) | 1.38 (0.8–2.38) | 1.35 (0.94–1.93) | Catalysis of the initial step of the mitochondrial fatty acid beta-oxidation pathway | |
| 1 (0.54–1.85) | 0.72 (0.4–1.28) | 0.81 (0.54–1.21) | Catalysis of to the synthesis of cholesteryl esters (using long chain fatty acyl coenzyme A) for intracellular storage | |
| 1 (0.56–1.79) | Possible marker of lipid accumulation in cells | |||
| 1 (0.52–1.91) | 0.6 (0.34–1.05) | 0.35 (0.24–0.53) | Catalysis of oxidation of polyunsaturated fatty acids with molecular oxygen | |
| 1 (0.56–1.79) | 1.2 (0.7–2.07) | 1.15 (0.8–1.66) | Intracellular transport and metabolism of lipids | |
| 1 (0.53–1.9) | 1.1 (0.63–1.91) | Membrane transport of long-chain fatty acids (LCFA) | ||
| 1 (0.55–1.83) | 0.99 (0.56–1.77) | 1.03 (0.7–1.51) | Fatty acid desaturase (formation of PUFA) | |
| 1 (0.55–1.81) | 1.18 (0.68–2.06) | 1.08 (0.75–1.56) | - ǁ - | |
| 1 (0.55–1.83) | 0.7 (0.39–1.27) | 0.73 (0.49–1.09) | No function confirmed | |
| 1 (0.54–1.85) | 0.94 (0.54–1.64) | 0.93 (0.63–1.39) | Glycerol uptake and metabolism | |
| 1 (0.52–1.91) | 1.11 (0.61–2.03) | β-subunit of mitochondrial trifunctional protein—involved in mitochondrial fatty acid β-oxidation pathway | ||
| 1 (0.55–1.81) | 1.09 (0.62–1.93) | 1 (0.69–1.47) | Biosynthesis of precursors for cholesterol and isoprenoids | |
| 1 (0.54–1.86) | 0.97 (0.53–1.77) | 0.94 (0.64–1.36) | Biosynthesis of precursors for cholesterol and isoprenoids | |
| 1 (0.55–1.82) | 0.84 (0.48–1.47) | 0.67 (0.46–0.98) | Regulator of HMGCR | |
| 1 (0.56–1.8) | 1.06 (0.61–1.82) | 1.06 (0.72–1.56) | Cholesterol uptake | |
| 1 (0.55–1.83) | Reduction of cellular level of cholesterol | |||
| 1 (0.53–1.88) | 1.3 (0.75–2.25) | 1.25 (0.79–1.99) | Arachidonic acid formation (hydrolysis of phospholipids); implicated in signal transduction, apoptosis, inflammation | |
| 1 (0.56–1.8) | 1.27 (0.74–2.19) | 1.01 (0.7–1.45) | Catalysis of the conversion of saturated fatty acids to monounsaturated fatty acids; likely to have wide-ranging effects on cellular membrane physiology, energy storage, and signaling | |
| 1 (0.56–1.8) | 0.82 (0.47–1.41) | 0.67 (0.47–0.96) | Monocarboxylate Transporters family member with no attributed function | |
| 1 (0.56–1.8) | Transport of LCFA across biological membranes, cholesterol metabolism regulation | |||
| 1 (0.55–1.81) | 1.11 (0.64–1.9) | 1.31 (0.9–1.9) | Catalysis of fatty acid activation but not fatty acid transport | |
| 1 (0.55–1.81) | 0.78 (0.53–1.14) | Esterification of cholesterol in the endoplasmic reticulum; Inhibition of | ||
| 1 (0.55–1.81) | 1.22 (0.68–2.18) | 1.12 (0.75–1.66) | Regulation of the expression of genes encoding enzymes required for fatty acid and cholesterol biosynthesis | |
| 1 (0.55–1.83) | 1.14 (0.66–1.98) | 1.1 (0.76–1.6) | - ǁ - | |
| 1 (0.54–1.84) | 1.17 (0.68–2.03) | 1.07 (0.74–1.54) | Postulated role in intracellular sterol transport or/and cholesterol biosynthesis | |
| 1 (0.54–1.85) | Inhibition of the uptake of free fatty acids and promotion of lipogenesis, induction of lipolysis, inhibition of the activity of lipid metabolism enzymes |
Fig 7In vivo transfection study of tumor cells using AP-15-based complexes.
Analyses of PCR products using DNA templates from: (a) B16-F10 tumors, injected with: 2-4- H2O, 5-7- AP-15/DOPE, 8-10- AP-15, 11-13- pSec, 14-16- pTIMP2, 17-20- AP-15/DOPE:pTIMP2 complexes, 21-24- AP-15:pTIMP2 complexes; 25- positive control for PCR (pTIMP2), (b) L1 tumors, injected with: 2-3- H2O, 4-5- AP-15, 6-7- AP-15/DOPE/DMEM, 8-14- AP-15:pTIMP2 complexes, 15-21- AP-15/DOPE/DMEM:pTIMP2 complexes; 25- positive control for PCR (pTIMP2). M- molecular weight size marker 1kb+, 1- reagent control for PCR.